Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q3 2019 Earnings Conference Call - Final Transcript

Nov 07, 2019 • 04:30 pm ET


Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q3 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, thank you for standing by and welcome to the Quarter Three of 2019 Earnings Conference Call. [Operator Instructions] Thank you.

Now I would like to hand the conference over to your first speaker today, Mr. Lauren Stival of Stern Investor Relations. Ma'am, you may begin.

Lauren Stival

Thank you. Good afternoon, everyone, and thank you for joining us to review Dicerna's third quarter 2019 financial results and operational highlights. For anyone who has not had a chance to review our results, we issued a press release after the close of trading today, which is available under the Investors & Media tab on our website at dicerna.com. You may also listen to this conference call via webcast on our website which will be archived for 30 days beginning approximately two hours after this call has been completed.

Speaking on today's call will be our President and CEO, Doug Fambrough, who will discuss our corporate progress and key milestones and provide an update on clinical development and collaboration activities. Our CFO, Jack Green will then review our third quarter financial results. We also have Jim Weissman, our Chief Operating Officer; and Ralf Rosskamp, our Chief Medical Officer, who will be available to answer questions during Q&A. Following our remarks, we will open the line for questions.

I'd like to remind listeners that management will be making forward-looking statements on today's call, including for example, plans and expected timeline for closing of the new Roche collaboration agreement; development of DCR-PHXC, DCR-HBVS, DCR-A1AT, and other pipeline programs; the timing of release of clinical data, alignment with FDA on regulatory approval requirements, the expansion of our programs into additional tissue types, expectations related to our collaborations with Roche, Lilly, Alexion, and Boehringer Ingelheim; expectations for discussions and possible opportunities with potential collaborators; and guidance regarding future collaboration revenue, operating expenses, and cash usage.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those disclosed in the Risk Factors section of Dicerna's latest forms 10-Q and 10-K filed with the SEC. We may elect to update these forward-looking statements at some point in the future. We specifically disclaim any obligation to do so if our views change.

Now I'd like to turn the call over to Doug, Dicerna's President and CEO. Doug?

Doug Fambrough

Thank you, Lauren. Good afternoon, everyone, and thank you for joining us. What an exciting time it is for us here at Dicerna. We are proud of the work we have accomplished over the years and particularly over the last five quarters as we deliver on the strategic goals we have set for ourselves. We have progressed from revealing initial proof-of-concept data in our DCR-PHXC program to starting dosing of our pivotal trial for that program. We have progressed two additional programs through clinical trial applications to initiate clinical development.

We signed three major licensing deals with Roche, Lilly, and Alexion. These collaborations have or will generate on closing in excess of $300